OraSure Technologies, Inc.OSURNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

globenewswire.com

OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital

BETHLEHEM, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has nominated two candidates, including the fund's founder Rishi Bajaj, to stand for election to the Company's Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders.

businesswire.com

Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors

LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has nominated two highly-qualified candidates, John Bertrand, Co-Founder of Digital Diagnostics, and Rishi Bajaj, President and CIO of Altai, for election to the OraSure Board of Directors (the “Board”) at the 2026 Annua.

zacks.com

OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device

OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth.

globenewswire.com

OraSure Technologies Issues Statement Regarding Altai Capital's Intent to Nominate Director Candidates

BETHLEHEM, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has notified the Company of its intent to nominate two candidates, including the fund's founder, Rishi Bajaj, to stand for election to the Company's Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders.

businesswire.com

Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors

LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. (“Altai”), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter notifying the OraSure Board of Directors (the “Board”) of Altai's intention to nominate two highly-qualified candidates, John Bertrand, CEO of Digital Diagnostics, and Rishi Bajaj, President and CI.

seekingalpha.com

OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript

OraSure Technologies, Inc. ( OSUR ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Jason Plagman - Vice President of Investor Relations Carrie Eglinton Manner - President, CEO & Director Kenneth McGrath - Chief Financial Officer Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the OraSure Technologies, Inc. 2025 Third Quarter Earnings Conference Call.

zacks.com

OraSure Technologies (OSUR) Reports Q3 Loss, Lags Revenue Estimates

OraSure Technologies (OSUR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.01 per share a year ago.

globenewswire.com

OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th

BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business developments for 5 p.m. ET on November 5, 2025.

globenewswire.com

OraSure Technologies Appoints Steven K. Boyd to its Board of Directors

Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective OraSure Board Has Added Three New Independent Directors in the Past Three Years Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of Steven K.

reuters.com

Exclusive: Altai Capital lays groundwork for board fight at OraSure Technologies, sources say

Altai Capital Management is preparing to launch a board fight at OraSure Technologies after the hedge fund, already one of the biggest owners of the medical device maker, increased its holdings, two people familiar with the matter told Reuters.

reuters.com

Exclusive: Healthcare entrepreneur's letter threatens 'adversarial path' after OraSure Tech rebuffs bid

Prominent healthcare entrepreneur Ron Zwanziger warned on Monday he may pursue a more "adversarial path" if the OraSure Technologies board continues to resist his offer to buy the medical devices company, according to a letter seen by Reuters.

fool.com

OraSure (OSUR) Q2 Revenue Falls 43%

seekingalpha.com

OraSure Technologies, Inc. (OSUR) Q2 2025 Earnings Call Transcript

OraSure Technologies, Inc. (NASDAQ:OSUR ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Carrie Eglinton Manner - President, CEO & Director Jason Michael Plagman - Vice President of Investor Relations Kenneth J. McGrath - Chief Financial Officer Conference Call Participants Noah Lewis - Raymond James & Associates, Inc., Research Division Operator Good day, and thank you for standing by.

zacks.com

OraSure Technologies (OSUR) Reports Q2 Loss, Beats Revenue Estimates

OraSure Technologies (OSUR) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.07 per share a year ago.

globenewswire.com

OraSure Appoints Anne Messing as Chief Commercial Officer

BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.

seekingalpha.com

OraSure Technologies: An Asymmetric Bet

OraSure trades near cash value with minimal debt, reflecting excessive market pessimism and creating an asymmetric risk-reward opportunity. The company's future hinges on Sherlock's at-home STD test kit, with a high probability of FDA approval and strong market potential. Management is actively streamlining operations, divesting non-core assets, and positioning OraSure as an attractive acquisition target.

globenewswire.com

OraSure to Announce Second Quarter 2025 Financial Results and Host Earnings Call on August 5th

BETHLEHEM, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2025 financial results and certain business developments for 5 p.m. ET on August 5, 2025.

reuters.com

OraSure Technologies received takeover bid from industry entrepreneur, sources say

Prominent healthcare entrepreneur Ron Zwanziger approached medical device maker OraSure Technologies with a takeover offer, three people familiar with the matter said, in what would mark more consolidation in the heavily fragmented diagnostic industry.

globenewswire.com

OraSure Launches Novel Blood Collection Device for Proteomic Research

The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research

seekingalpha.com

Orasure Technologies: Multiple Shots To Deliver Value

OSUR remains deeply undervalued, trading below liquidation value, with a robust, cash-rich, debt-free balance sheet providing downside protection. Key value drivers include a 20% share buyback, potential building sale, and new product launches both in-house and via partnerships. Operational improvements—cost reductions, automation, and product diversification—should support gross margins and future growth.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance